Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046293 · ClinicalTrials.gov registry record · Phase 2
ReoPro and Retavase to Treat Acute Stroke
A Phase 2 study of Cerebrovascular Accident, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 3
- Study locations
NCT00046293: Completed Phase 2 study of Cerebrovascular Accident, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
NCT00046293 is a Phase 2 study of Cerebrovascular Accident that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 72 participants, below the 515-participant average among 26 other Cerebrovascular Accident trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00046293, a Phase 2 study of Cerebrovascular Accident, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will determine the dose of Retavase that can safely be combined with ReoPro in treating acute ischemic stroke (stroke resulting from a blood clot in the brain). ReoPro and Retavase are currently approved by the Food and Drug Administration to treat heart problems caused by blockage of heart arteries. The only therapy approved by the Food and Drug Administration to treat ischemic stroke is the clot buster drug rt-PA. This treatment is effective only if begun within 3 hours of onset of the stroke, however, and most patients do not get to the hospital early enough to benefit from it. Patients between 18 and 80 years of age who have had a mild or moderate acute stroke between 3 and 24 hours before starting study drugs may be eligible for this study. Candidates will be screened with a medical history and physical examination, blood tests, rating of neurological deficits such as cognition deficits or problems walking that resulted from the stroke, and a computed tomography (CT) scan of the head. CT involves the use of specialized X-rays to obtain images of the brain. The patient lies on a table that is moved into a cylindrical machine (the scanner) for the imaging study, which usually takes about 5 to 10 minutes. All participants will receive 0.25 mg/kg of ReoPro (maximum dose of 30 mg). The drug is infused into the vein over 12 hours. Some patients will also receive one of four doses of Retavase, which may boost the effectiveness of ReoPro in opening the blocked blood vessel. Retavase is given through a needle in the vein over 2 minutes. Patients will be monitored daily until discharge from the hospital, or until day 5, whichever is earlier. Assessments will include physical examinations, blood tests to examine factors involved in blood clotting, and CT scans to evaluate both the response to treatment and drug side effects. They will return for a follow-up examination and CT scan 30 days after treatment. ...
Conditions Studied
Interventions
- DRUG Reopro
- DRUG Retrovase
Study Locations (3)
Maryland
- Suburban Hospital - Bethesda
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
District of Columbia
- Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2002-09-24 |
| Est. Completion | 2007-07-20 |
| Phase | Phase 2 |
What the finished NCT00046293 record still lists
NCT00046293 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 515-participant average among 26 other Cerebrovascular Accident trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Cerebrovascular Accident appearing as the primary indexed condition, and to 2 interventions - of which Reopro is the first listed.
NCT00046293 reports a single indexed study location in Maryland, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00046293 about?
NCT00046293 is a clinical study titled "ReoPro and Retavase to Treat Acute Stroke". This study will determine the dose of Retavase that can safely be combined with ReoPro in treating acute ischemic stroke (stroke resulting from a blood clot in the brain). ReoPro and Retavase are currently approved by the Food and Drug Administration to treat heart problems caused by blockage of hea...
What is the current status of trial NCT00046293?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2002-09-24. Estimated completion is 2007-07-20.
What conditions does trial NCT00046293 study?
This clinical trial studies the following conditions: Cerebrovascular Accident.
What interventions are being tested in trial NCT00046293?
The interventions under investigation include: Reopro (DRUG), Retrovase (DRUG).
Who is sponsoring clinical trial NCT00046293?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00046293 being conducted?
This trial has 3 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebrovascular Accident
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00046293's enrollment target sits among peer trials
72 14th of 26 higher than 13 of 26 other Cerebrovascular Accident trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cerebrovascular Accident trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dietary Nitrate Supplements and Ischemic Stroke Recovery
COMPLETED · Phase 2
-
Motor Recovery in Recent Stroke Patients Treated With Amphetamine and Physical Therapy
COMPLETED · Phase 2
-
Home-based Telehealth Stroke Care: A Randomized Trial for Veterans
COMPLETED · Phase 2
-
Stroke Rehabilitation Outcomes With Supported Treadmill Ambulation Training
COMPLETED · Phase 2
-
Combining Armodafinil With Neuro-rehabilitation to Improve Neurological Recovery and Reduce Disability Post-Stroke
COMPLETED · Phase 2
-
Cardiac Rehabilitation of Stroke Survivors (SRP-CROSS)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI